Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 29Meningioma 5Gastro-enteropancreatic neuroendocrine tumor 5Paraganglioma 4Carcinoma, Neuroendocrine 4Pheochromocytoma 3Neuroblastoma 3Neoplasms, Germ Cell and Embryonal 2Neoplasms 2Medulloblastoma 2Glioma 2Ependymoma 2Carcinoma, Merkel Cell 2Carcinoma, Medullary 2Carcinoid Tumor 2Adenoma, Islet Cell 2Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Pancreatic Diseases 1Osteosarcoma 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1

Interventions

pembrolizumab 2fludarabine 2Radiosurgery 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1regorafenib 1pazopanib 1niraparib 1neratinib 1lutetium Lu 177 dotatate 1ibrutinib 1grapiprant 1fludarabine phosphate 1famitinib 1encorafenib 1copanlisib 1cemiplimab 1capivasertib 1camrelizumab 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Disease Progression × lutetium Lu 177 dotatate × Clear all
NCT04954820 2026-06-04

ReLUTH

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Recruiting
146 enrolled
EndocrineNET

Neuroendocrine Tumors, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡